BTIG Research downgraded Zimmer Biomet from Buy to Neutral
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/23/2026 | Buy → Neutral | BTIG Research | |
| 2/20/2026 | Mkt Perform | William Blair | |
| 1/9/2026 | $93.00 | Neutral → Sell | Goldman |
| 1/6/2026 | Outperform → Mkt Perform | Raymond James | |
| 1/5/2026 | $210.00 | In-line → Outperform | Evercore ISI |
| 12/16/2025 | $100.00 | Outperform → Neutral | Robert W. Baird |
| 11/6/2025 | $100.00 | Overweight → Neutral | Analyst |
| 9/18/2025 | $130.00 | Buy | Rothschild & Co Redburn |
BTIG Research downgraded Zimmer Biomet from Buy to Neutral
William Blair initiated coverage of Zimmer Biomet with a rating of Mkt Perform
Goldman downgraded Zimmer Biomet from Neutral to Sell and set a new price target of $93.00
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
8-K - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)
SD - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)
SCHEDULE 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
WARSAW, Ind., June 2, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8 with a fireside chat at 10:40 a.m. ET. A live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the fireside chat.About Zimmer BiometZimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize
WARSAW, Ind., May 22, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the second quarter of 2026. The cash dividend of $0.24 per share is payable on or about July 31, 2026 to stockholders of record as of the close of business on June 25, 2026. About Zimmer BiometZimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessl
WARSAW, Ind., May 12, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it now anticipates repurchasing up to $1 billion of its common stock during fiscal year 2026, a $250 million increase from the company's prior assumption. All repurchases are expected to be made under the company's existing $1.5 billion share repurchase authorization, which was approved by the Zimmer Biomet Board of Directors and announced in February 2026. The company has not made any changes to the size, duration or terms of that
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
Experienced orthopedic surgeon from the Hospital for Special Surgery, innovator and former Chief Medical Technology Advisor joins company in an elevated capacityWARSAW, Ind., April 7, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Jonathan M. Vigdorchik, M.D., as Chief Science, Technology and Medical Affairs Officer, effective April 14. In this role, Dr. Vigdorchik will oversee the strategy, delivery, and management of the company's global end-to-end technology portfolio, including AI,
Dr. Jonathan M. Vigdorchik Named Chief Medical Technology Advisor, Adult Reconstruction and Hip Implants Dr. Anand M. Murthi Appointed Chief Medical Advisor, Shoulder, Sports, Extremities, and Trauma (S.E.T.) WARSAW, Ind., Aug. 28, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointments of Jonathan M. Vigdorchik, MD, as Chief Medical Technology Advisor focused on Adult Reconstruction and Hip Implants, and Anand M. Murthi, MD, FAAOS, as Chief Medical Advisor, Shoulder, Sports, Extremities, and Trauma (S.E.T.). As strategic advisors, Drs. Vigdorchik and Murthi will leverage their extensive clinical experience t
WARSAW, Ind., May 27, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Kevin Thornal as Group President, Global Businesses and the Americas. Reporting to Chairman-Elect, President and CEO Ivan Tornos, Mr. Thornal will join the Company on July 1, 2025 to oversee the Americas commercial organization and lead business strategy and execution for its global Knees, Hips, S.E.T. and Data, Technology, and Enabling Solutions units. "Kevin is an incredible addition to our leadership team at an e
SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
SC 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
WARSAW, Ind., May 22, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the second quarter of 2026. The cash dividend of $0.24 per share is payable on or about July 31, 2026 to stockholders of record as of the close of business on June 25, 2026. About Zimmer BiometZimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessl
First quarter net sales of $2.087 billion increased 9.3% on a reported basis, 6.8% on a constant currency1 basis and 2.9% on an organic constant currency1 basisFirst quarter diluted earnings per share were $1.22, an increase of 34.1%; adjusted1 diluted earnings per share were $2.09, an increase of 15.5%Company updates full-year 2026 financial guidanceWARSAW, Ind., April 28, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended March 31, 2026. The Company reported first quarter net sales of $2.087 billion, an increase of 9.3% over the prior year period, an increase of 6.8% on a constant currency1 basis and an increase of
WARSAW, Ind., April 9, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced its first quarter earnings conference call will be webcast on Tuesday, April 28, 2026, at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. A live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call.Individuals in the U.S. and Canada who wish to dial int